Ask AI
ProCE Banner Activity

Patient Resource for Immunotherapy-Eligible Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

PDF

This patient-friendly resource provides practical explanations on what immunotherapy is, how it works, and what to expect during treatment. It also highlights common side effects and includes a checklist of symptoms that should prompt patients to contact their care team.

Released: February 18, 2026

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Merck Sharp & Dohme LLC.

Merck Sharp & Dohme, LLC

Target Audience

This activity is intended for oncologists, nurse practitioners, physician associates, nurses, pharmacists, and other healthcare professionals caring for patients with newly diagnosed advanced/metastatic NSCLC in rural community cancer practices.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients with newly diagnosed advanced/metastatic NSCLC at risk for health inequities due to access to care, race/ethnicity, age, or other sociodemographic factors

  • Implement best practices in molecular testing and interpreting results to identify every patient with newly diagnosed advanced/metastatic NSCLC eligible for immunotherapy

  • Collaborate with each patient and the multidisciplinary team to personalize an immunotherapy-based treatment plan for newly diagnosed advanced/metastatic NSCLC with consideration for the latest data, expert recommendations, and patient preferences

  • Educate all eligible patients and their caregivers on the risk–benefit profile and goals of immunotherapy-based treatment using effective communication strategies and resources

  • Manage immune-related adverse events associated with immunotherapy-based treatments to maximize quality of life and clinical outcomes in each patient with newly diagnosed advanced/metastatic NSCLC

Disclosure

Primary Author

Jamie E. Chaft, MD: consultant/advisor/speaker: AstraZeneca, Boehringer Ingelheim, Foundation Medicine, Genentech, Guardant, Lilly, Merck, Natera, Nuvation Bio, Revolution Medicines; researcher (paid to institution): AstraZeneca, BioNTech, Boehringer Ingelheim, Genentech, Lilly, Merck.

Ticiana Leal, MD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Black Diamond, Catalyst, Gilead, Jazz, Johnson & Johnson, Naterra, Novocure, Nuvation Bio, Pfizer, Roche, Summit Therapeutics, Synthekine, Verastem.